# XO Life

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xo-life

- Industry: Healthcare IT
- Headquarters: Munich, Germany
- Website: www.xo-life.com
- Total disclosed funding: $2.3M
- Latest round: Seed (Feb 16, 2022)
- Investors on record: 3

## About

Based in Munich, Germany, and founded in 2018 by CEO Friderike Bruchmann, XO Life GmbH is a MedTech company that connects patients and pharma manufacturers to better understand patients.  In August 2024, the company raised EUR 7 million in venture funding co-led by Sandwater and Grazia Equity, with participation from Aescuvest, Winning Mindset Ventures, Isartal Ventures, MediVentures, capacura,Vi Partners, Bayern Kapital, and other unspecified investors.

XO Life provides the impact monitor, a real-world evidence platform that allows patients to answer questions related to their therapies, medicines, and health conditions and generates data-driven insights on drug effectiveness and safety profiles. The company also provides digital pharmacovigilance, a digital end-to-end software-as-a-service solution to pharma companies for drug safety data intake, communication, and evaluation.

The company will use the August 2024 funding for its international expansion.

## Funding rounds

- Seed, Feb 16, 2022, $2.3M — MediVentures, SeedLink SL, Aescuvest

## Investors

- MediVentures — Seed
- SeedLink SL (https://capitalatlas.ai/funds/seedlink-sl) — Seed
- Aescuvest (https://capitalatlas.ai/funds/aescuvest) — Seed